Krystal Biotech buy Guggenheim
Start price
28.02.23
/
50%
€77.50
Target price
28.02.24
€95.04
Performance (%)
93.55%
End price
29.02.24
€150.00
Summary
This prediction ended on 29.02.24 with a price of €150.00. With a performance of 93.55% the BUY prediction by Guggenheim was a big success. Guggenheim has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | 6.921% | 6.921% | -33.115% |
| iShares Core DAX® | -0.727% | 2.783% | 28.954% |
| iShares Nasdaq 100 | 1.839% | 5.294% | 5.747% |
| iShares Nikkei 225® | -2.033% | -0.196% | -4.367% |
| iShares S&P 500 | 1.334% | 4.044% | 5.224% |
Comments by Guggenheim for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $101.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten
Current prediction by Guggenheim for Krystal Biotech
Stopped prediction by Guggenheim for Krystal Biotech
Krystal Biotech
Start price
Target price
Perf. (%)
€152.00
27.02.24
27.02.24
€161.18
27.02.25
27.02.25
14.14%
28.02.25
28.02.25
